Dopamine and depression: The forgotten neurotransmitter;Dopamine et dépression: Le neurotransmetteur oublié

Revue Medicale de Liege

Volumn 63, Issue 5-6, 2008, Pages 378-384

  Pitchot, W ^a   Scantamburlo, G ^a   Ansseau, M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Antidepressant; Apomorphine; Brain imaging; Depression; Dopamine; Mesolimbic system

Indexed keywords

AMFEBUTAMONE; AMINEPTINE; AMISULPRIDE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; DOPAMINE; ENTACAPONE; ISOCARBOXAZID; MINAPRINE; NEUROTRANSMITTER; NIALAMIDE; NOMIFENSINE; PERGOLIDE; PHENELZINE; PRAMIPEXOLE; ROPINIROLE; ROXINDOLE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TOLCAPONE; VENLAFAXINE;

DEPRESSION; DOPAMINERGIC SYSTEM; HUMAN; IMAGING SYSTEM; LIMBIC SYSTEM; NEUROIMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNAPSE;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DOPAMINE; DOPAMINE ANTAGONISTS; HUMANS;

EID: 47249160805     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Dunlop BW, Nemeroff CB. - The role of dopamine in the pathophysiology of depressivo. Arch Gene Psychiatry, 2007, 64, 327-337.
2. Lemke MR, Fuchs G, Gemende I, et al. - Depression and Parkinson's disease. J Neurol, 2004, 251, 24-27.
3. Willner P, Hale AS, Argyropoulos S. - Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Disord, 2005, 86, 37-45.
4. Millan MJ. - The role of monoamines in the actions of established and «novel» antidepressant agents : a critical review. Eur J Pharmacol, 2004, 500, 371-384.
5. Willner P. - Dopaminergic mechanisms in depression and mania. In : Bloom FE, Kupfer DJ (Editors). Psychopharmacology : The fourth Generation of Progress. New York, Raven Press Ltd. 1995, 921-931.
6. Roy A, Pickar D, Linnoila M, et al. - Plasma norepinephrine level in affective disorder. Relantionship to melancholia. Arch Gen Psychiatry, 1995, 42, 1181-1185.
7. Engstrom G, Alling C, Blennow K, et al. - Reduced cerebrospinal HVA concentratieons and HVA/5-HIAA ratios in suicide temper. Monoamine metabolites in 120 suicide temper and 47 controls. Eur Neuropsychopharmacol, 1999, 9, 399-405.
8. Pitchot W, Gonzalez Moreno A, Hansenne M, et al. - Rôle du système dopaminergique dans la dépression : corrélate cliniques du test à l'apomorphine. Acta Psychiat Belg, 1993, 93, 343-358.
9. Pitchot W, Reggers J, Pinto E, et al. - Catecholamine and HPA axis dysfunction in depression : relationship with suicidal behavior. Neuropsychobiology, 2003, 47, 152-157.
10. Ansseau M, von Frenckell R, Cerfontaine JL, et al. - Blunted response of growth hormone to clonidine and apomorphine in endogenous depression. Br J Psychiatry, 1988, 153, 65-71.
11. Pitchot W, Hansenne M, Gonzalez Moreno A et al. - Effect of previous antidepressant therapy on the ,growth hormone response to apomorphine. Neuropsychobiology, 1995, 32, 19-22.
12. Pitchot W, Hansenne M, Gonzalez Moreno A, et al. - Reduced dopamine function in depressed patients is related to suicidal behavior but not its lethality. Psychoneuroendochnology, 2001a, 26, 689-696.
13. Pitchot W, Hansenne M, Ansseau M. - Role of dopamine in non-depressed patients with a history of suicide attempt. Eur Psychiatry, 2001b, 26, 331-335.
14. Verbeeck WJC, Berk M, Paiker J, et al. - The prolactin response to sulpiride in major depression : the role of the D2 receptor in depression. Eur Neuropsychopharmacol, 2001,11, 215-220.
15. Mc Pherson H, Walsh A, Silverstone T. - Growth hormone and prolactin response to apomorphine in bipolar and unipolar depression. J Affect Disord, 2003, 76, 121-125.
16. Laasonen-Balk T, Kuikka J, Viinamaki H, et al. - Striatal dopamine transporter density in major depression. Psychopharmacology, 1999, 144, 282-285.
17. Drevets WC, Gautier C, Price JC, et al. - Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry, 2001, 49, 81-96.
18. Suhara T, Nakayama K, Inoue O, et al. - D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology, 1992, 106, 14-18.
19. D'haenen H, Bossuyt A. - Dopamine D2 receptors in the brain measured with SPECT. Biol Psychiatry, 1994, 35, 128-132.
20. Shah PJ, Ogilvie AD, Goodwin GM. - Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Medecine, 1997, 27, 1247-1256.
21. Parsey RV, Oquendo MA, Zea-Ponce Y, et al. - Dopamine D2 receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry, 2001, 50, 313-322.
22. Bressan RA, Costa DC, Jones HM. - Typical antipsychotic drugs - D2 receptors occupancy and depressive symptoms in schizophrenia. Schizophrenia Res, 2002, 56, 31-36.
23. Willner P. - Dopamine and depression. In : Di Chiara, G. (Ed.), Handbook of Experimental Pharmacology : Dopamine in the CNSS, Springer, Berlin, 2002, 387-416.
24. Devoto P, Flore G, Pira L. - Alpha2-adrenoreceptors mediated co-release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex. J Neurochem, 2004, 88, 1003-1009.
25. Papakostas GI. - Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacology, 2006, 16, 391-402.
26. Thase ME, Trivedi MH, Rush AJ. - MAOIs in the contemporary treatment of depression. Neuropsychopharmacology, 1995, 12, 185-219.
27. Fava M, Rosenbaum JF, Kolsky AR. - Open study of the catechol-o- methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacology, 1999, 19, 329-335.
28. Mischoulon D, Nierenberg AA, Kizilbash L. - Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment : A survey of clinicians. Can J Psychiatry, 2000, 45, 844-850.
29. Zisook S, Rush AJ, Haight BR. - Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry, 2006, 59, 203-210.
30. Rampello L, Nicoletti F. - Dopamine and depression : therapeutic implications. CNS Drugs, 2000, 13, 35-45.
31. Willner P. - The mesolimbic dopamine system as a target for rapid antidepressant action. Intern Clin Psychopharmacology, 1997, 12, 7-14.
32. Corrigan MH, Denahan AQ, Wright CE. - Comparison of pramipexole, fluoxetine and placebo in patients with major depression. Depress Anxiety, 2000, 11, 58-65.
33. Sporn J, Ghaemi SN, Sambur MR, et al. - Pramipexole augmentation in the treatment of unipolar and bipolar depression : a retrospective chart review. Ann Clin Psychiatry, 2000, 12, 137-140.
34. Pitchot W, Floris M, Souery D et al. - Système dopaminergique, depression et antidépresseurs. Acta Psychiatric Belgica, 2005, 106, 5-13.
35. Cassano P, Lattanzi L, Soldani, et al. - Pramipexole in treatment-resistant depression : an extended follow-up. Depress Anxiety, 2004, 20, 131-138.
36. Zarate CA, Payne JL, Singh J, et al. - Pramipexole for bipolar II depression : a placebo-controlled proof of concept study. Biol Psychiatry, 2004, 56, 54-60.
37. Goldberg JF, Burdick KE, Endick CJ. - Preliminary randomized,double- blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry, 2004, 161, 564-566.
38. Cassano P, Lattanzi L, Fava M, et al. - Ropinirole in treatment-resistant depression : a 16-week pilot study. Can J Psychiatry, 2005, 50, 357-360.